SOCM
ENGN icon

SR One Capital Management’s enGene Therapeutics ENGN Stock Holding History

SR One Capital Management’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.09M Hold
747,750
– – 0.56% 13
2025
Q4 		$6.75M Hold
747,750
– – 0.96% 11
2025
Q3 		$5.11M Hold
747,750
– – 0.74% 12
2025
Q2 		$2.72M Hold
747,750
– – 0.59% 13
2025
Q1 		$3.35M Hold
747,750
– – 0.86% 12
2024
Q4 		$4.97M Hold
747,750
– – 1.21% 10
2024
Q3 		$4.94M Buy
747,750
+247,750
+50% +$1.84M 0.99% 10
2024
Q2 		$4.71M Buy
+500,000
New +$6.41M 1.48% 8

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

SR One Capital Management's ENGN Position: Q1 2026 in Review

SR One Capital Management held its enGene Therapeutics (ENGN) position steady in Q1 2026 at 747,750 shares worth $5.09M. The position accounts for 0.56% of the portfolio, ranked #13.

SR One Capital Management first reported a position in ENGN in Q2 2024 and has held it in 8 quarters since. The position peaked at $6.75M in Q4 2025. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

  • SR One Capital Management held 747,750 shares of enGene Therapeutics worth $5.09M as of Q1 2026.
  • SR One Capital Management left its enGene Therapeutics share count unchanged in Q1 2026.
  • enGene Therapeutics made up 0.56% of SR One Capital Management's portfolio in Q1 2026, its #13 holding.
  • SR One Capital Management first reported a position in enGene Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • SR One Capital Management's enGene Therapeutics position peaked at $6.75M in Q4 2025.
  • 61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on SR One Capital Management's 13F filing for Q1 2026, filed 14 May 2026.